GlaxoSmithKline Announces Positive Results for Triple-Therapy Inhaler
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) on Wednesday reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for patients with chronic obstructive pulmonary disease.
The Trelegy Ellipta is approved by the U.S. Food and Drug Administration and designed to be used once daily for long-term maintenance treatment.
GlaxoSmithKline said the Trelegy Ellipta study, which involved 10,355 patients, showed significant reductions in the annual rate of on-treatment exacerbations when compared with the dual-therapy treatments it has in its portfolio.
Write to Oliver Griffin at firstname.lastname@example.org
(END) Dow Jones Newswires
September 20, 2017 03:00 ET (07:00 GMT)